Issue 3: Prior Authorization for High-Cost Drugs Administering a biologic, GLP-1 agent, or extended-release injectable without prior authorization results in denial of both the administration code and the drug J-code
While epidemiological associations are well-established, the underlying molecular mechanisms and long-term consequences require systematic evaluation
Subcutaneous or intranasal administration bypasses hepatic metabolism, meaning a 1mg intranasal dose may produce plasma concentrations equivalent to 22.5mg oral
Reizine F, Lesouhaitier M, Gregoire M, Pinceaux K, Gacouin A, Maamar A, et al
The definitive way to confirm a peptide is laboratory analysis: high-performance liquid chromatography (HPLC) measures purity, mass spectrometry (MS) confirms molecular identity, and a Limulus Amebocyte Lysate (LAL) assay screens for bacterial endotoxins